JPMorgan Chase & Co. Raises Insmed (NASDAQ:INSM) Price Target to $92.00
Insmed (NASDAQ:INSM – Free Report) had its price objective lifted by JPMorgan Chase & Co. from $83.00 to $92.00 in a report released on Friday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other equities analysts also recently commented on INSM. HC Wainwright restated a “buy” rating and issued […]
Insmed (NASDAQ:INSM – Free Report) had its price objective lifted by JPMorgan Chase & Co. from $83.00 to $92.00 in a report released on Friday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other equities analysts also recently commented on INSM. HC Wainwright restated a “buy” rating and issued […]
